Novartis stock popped Thursday — prompting Travere Therapeutics to slide — after winning FDA approval for a kidney disease treatment.

Novartis is uniquely positioned to lead a transformation in kidney care Vanrafia was granted accelerated approval based on a prespecified interim analysis of the Phase III ALIGN study measuring ...

Amid all the volatility, some companies are proving resilient by performing much better than the market. Some of these look ...

The Food and Drug Administration (FDA) has granted accelerated approval to Vanrafia ® (atrasentan) to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid ...

Richard Lafayette, MD, FACP, Stanford University Medical Center, explains the significance of this second approval in a month ...

As targeted treatments such as Tarpeyo (Calliditas), Filspari (Travere), Fabhalta (Novartis), and most recently Vanrafia (Novartis) enter the market, this research captures how patients are ...

Novo Nordisk is licensing a drug called LX9851 from Lexicon Pharmaceuticals for up to $75 million in upfront and near-term ...

Su principio activo, atrasentan, ha sido desarrollado por la compañía estadounidense Chinook Therapeutics adquirida por Novartis en 2023 por 3.200 millones de dólares. 'Vanrafia' está indicado ...

As targeted treatments such as Tarpeyo (Calliditas), Filspari (Travere), Fabhalta (Novartis), and most recently Vanrafia (Novartis) enter the market, this research captures how patients are navigating ...